Adriamycin and the Heart

Publisher Website
Google Scholar
Abstract
Doxorubicin, or adriamycin, is one of the most effective chemotherapeutic agents for cancer. It has an established role in the treatment of the acute leukemias and the lymphomas. In contrast to most other drugs, it has substantial activity in solid tumors as well. It is the single most effective agent in the treatment of breast cancer and soft-tissue sarcomas, and it has substantial activity in the childhood tumors, testicular cancer, gastric cancer, ovarian cancer and oat-cell carcinoma of the lung.1 The acute dose-limiting toxicity of this drug, as with most chemotherapeutic agents, is myelosuppression. Other side effects, including nausea, vomiting . . .